High Grade Hepatotoxicity From Dual Checkpoint Inhibitors Is More Common in Hepatocellular Carcinoma Than Other Cancers
We identified an elevated risk of liver injury in HCC patients receiving ICIs compared to ICI-treated non-HCC cancers and sorafenib-treated HCC, with dual ipilimumab-nivolumab therapy carrying the highest risk.
Authors
- Niharika Mallepally
- Jeffrey Kahn (ORCID: https://orcid.org/0000-0001-8618-4776)
- Evanthia T. Roussos Torres (ORCID: https://orcid.org/0000-0002-0740-5102)
- Jennifer L. Dodge
- Lily Dara (ORCID: https://orcid.org/0000-0002-0121-7186)
- Elsie Ennin (ORCID: https://orcid.org/0009-0001-0089-2075)
- Layla Shojaie (ORCID: https://orcid.org/0000-0002-5020-5181)
- Myra Ali
- Kali Zhou (ORCID: https://orcid.org/0000-0001-8554-2906)
- Sean Dewberry
- Melissa Trieu
Institutions
- University of Southern California (US)
- Huntington Medical Research Institutes (US)
- Huntington Hospital (US)
- University of California, Los Angeles (US)
- USC Norris Comprehensive Cancer Center (US)
Publication Details
- Journal
- Liver International
- Published
- 2025-08-08
- DOI
- https://doi.org/10.1111/liv.70255
- Citations
- 3
- Primary Topic
- Drug Transport and Resistance Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences